Skip to main content

INSIGHTS AND PERSPECTIVES

  • Gluten may not influence babies' risk of developing Type 1 diabetes

    NEW YORK — Introducing a gluten-free diet to an infant may not reduce its risk of developing Type 1 diabetes, according to a new study published in Diabetes Care.

    German researchers analyzed data pooled from 150 infants with a first-degree family history of Type 1 diabetes and randomly exposed them to gluten at the age of 6 months (control group) or 12 months (late-exposure group). The infants then were followed until 3 years of age (and annually thereafter for safety purposes).

  • Study: Diabetics at higher risk of tuberculosis infection

    NEW YORK — Researchers from the University of Texas Health Science Center at Houston found that patients with diabetes are at higher risk of contracting tuberculosis, a deadly bacterial disease, than nondiabetics.

    The study investigators discovered among 233 patients that were diagnosed with TB between March 2006 and March 2008 — which included 61 patients in southern Texas and 172 in northeastern Mexico — 25% of TB cases were attributed to the presence of diabetes, while 6% of TB cases were caused by HIV.

  • Study: CT scans could help predict early death among diabetes patients

    WAKE FOREST, N.C. — A common test may help predict early death among diabetes patients, a new study found.

    According to research lead by Donald Bowden, director of the Center for Diabetes Research at Wake Forest Baptist Medical Center, the examination of a patient's coronary artery calcium score — which measures the amount of calcified plaque buildup in blood vessels — through a computed tomography scan, or CT scan, could indicate the patient's risk of coronary heart disease, which can lead to premature death.

  • Study: Ragweed, mold behind rise in allergies

    MADISON, N.J. — Ragweed and mold are driving increased allergies across America, Quest Diagnostics reported Monday.

    In the study, sensitization rates to common ragweed and mold increased the most of the 11 common allergens evaluated over a four-year period. Sensitization to common ragweed grew 15% nationally, while mold grew 12%. By comparison, sensitization to the 11 allergens combined increased 5.8%.

  • CVS Caremark outlines results of personalized consumer communications program

    WOONSOCKET, R.I. — CVS Caremark outlined on Tuesday at a consumer health engagement conference the results of a personalized consumer communications program designed to encourage patients to take their medications as doctors direct.

    Early results of the program showed increases in consumers signing up for automatic prescription refills and more readily substituting branded medications for generic medicines to lower costs.

  • Gestational diabetes risk increases among women that gain weight between first, second pregnancies

    OAKLAND, Calif. — Women that experience body mass index gains between their first and second pregnancies are at an increased risk of developing gestational diabetes in the second pregnancy, according to a Kaiser Permanente study.

  • Tribenzor well-tolerated among older patients in study

    PARSIPPANY, N.J. — A drug made by Daiichi-Sankyo was safe and effective in maintaining reductions in blood pressure in older patients, according to a new study presented at the American Society of Hypertension’s 26th annual meeting in New York.

    The “TRINITY” study of Tribenzor (olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide) showed the drug was well-tolerated and effective in patients ranging in age from younger than 65 years to older than 65 years, after a year.

  • PhRMA: California-based drug makers focusing on heart disease, cancer treatments

    WASHINGTON — California-based companies are developing nearly more than one-fifth of the drugs to treat some of the deadliest diseases in the world, according to an analysis by the drug industry lobby.

    According to two Pharmaceutical Research and Manufacturers of America reports released this year, of the 1,186 drugs under development for heart disease and cancer, 243 were from California companies. These include 188-of-the-887 drugs for more than 20 types of cancer, and 55-of-the-299 drugs for heart disease and stroke.

X
This ad will auto-close in 10 seconds